Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Sponsor: Hyundai Pharm
Summary
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
Official title: A Clinical Study to Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2024-06-20
Completion Date
2024-11-30
Last Updated
2024-08-29
Healthy Volunteers
Yes
Conditions
Interventions
Empagliflozin 25 MG
PO, QD
Ezetimibe/Rosuvastatin 10/10mg
PO, QD
Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
PO, QD
Locations (1)
Kyungpook national university hospital
Daegu, Gyeongsangbuk-do, South Korea